Publications by authors named "A Yoritaka"
In super-aged societies, dementia has become a critical issue, underscoring the urgent need for tools to assess cognitive status effectively in various sectors, including financial and business settings. Facial and speech features have been tried as cost-effective biomarkers of dementia including Alzheimer's disease (AD). We aimed to establish an easy, automatic, and extensive screening tool for AD using a chatbot and artificial intelligence.
View Article and Find Full Text PDFPatients with Parkinson's disease (PD) experience significantly reduced quality of life when PD is complicated with Pisa syndrome (PS). PS is a postural abnormality associated with a lateral bending of the trunk, causing the patient to lean to one side. Microsaccades during fixation are transmitted to the visual cortex, and this gaze movement may be impaired in PD.
View Article and Find Full Text PDFArticle Synopsis
- Safinamide is shown to be an effective adjunctive treatment for managing wearing-off symptoms in older patients with Parkinson's disease who are already on levodopa therapy.
- In a study involving 24 participants (mostly aged 75 and older), significant improvements were observed in various assessments of motor and non-motor symptoms after 18 weeks of treatment.
- Despite some mild adverse events, the findings indicate that safinamide improves quality of life without introducing new safety concerns.
Article Synopsis
- Istradefylline (IST) is investigated as an adjunctive treatment for Parkinson's disease (PD) to see if it can reduce the need for higher doses of levodopa, which is commonly linked to motor complications.
- In a study with 114 PD patients experiencing wearing-off symptoms, those receiving IST required significantly less additional levodopa over 37 weeks compared to those who did not receive IST.
- Patients treated with IST also showed improvements in motor functions measured by rating scales and wearable devices, suggesting that IST may enhance symptom management without increasing levodopa dosage significantly.
Objective: It is difficult to distinguish patients with schizophrenia with neuroleptic-induced parkinsonism (NIP) from those with existing idiopathic Parkinson's disease when their striatal dopamine transporter uptake is reduced. There is a possibility of misdiagnosis of Parkinson's disease in patients with schizophrenia as schizophrenia with NIP, which leads to inappropriate treatment. This prospective study aimed at determining the underlying pathophysiology using detailed clinical and psychological assessments.
View Article and Find Full Text PDF